4.5 Article

Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice

Journal

MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 325, Issue 1-2, Pages 101-109

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2010.05.016

Keywords

Anti-resorptive; Estrogen receptor; Selective estrogen receptor modulator; Osteogenic; Bone microarchitecture

Funding

  1. Ministry of Health and Family Welfare, Department of Biotechnology and Department of Science and Technology, Government of India
  2. Le Conseil Regional de Picardie
  3. Council of Scientific and Industrial Research
  4. University Grants Commission, Government of India.

Ask authors/readers for more resources

Medicarpin, a pterocarpan class of naturally occurring benzopyran furanobenzene compound was synthesized in gram scale to investigate its effects on murine bone cells and in ovariectomized (OVx) mice. Medicarpin, at as low as 10(-10) M suppressed osteoclastogenesis in bone marrow cells (BMCs). Medicarpin-induced apoptosis of mature osteoclasts isolated from long bones. Effects of medicarpin in osteoclasts appear to be independent of estrogen receptor (ER) activation as ICI 180,782 failed to abrogate its effects on osteoclasts. In calvarial osteoblasts, medicarpin (10(-10) M) blocked nuclear factor kappaB (NF-kappa B) signaling assessed by tumor necrosis factor alpha (TNF alpha)-stimulated nuclear translocation of p65 subunit of NF-kappa B. Medicarpin also inhibited the expression of TNF alpha in mouse calvarial osteoblasts. This effect was ER dependent as ICI 180,782 reversed the suppressive effect of medicarpin on TNF alpha mRNA levels in osteoblasts. In addition, like 17 beta-estradiol, presence of medicarpin inhibited TNF alpha-induced upregulation of interleukin-1, and -6 mRNA levels in osteoblasts. In co-cultures consisting of calvarial osteoblasts and BMCs, presence of medicarpin increased osteoprotegerin (OPG)/receptor activator of NF-kappa B ligand (RANKL) ratio and reduced mRNA levels of osteoclast markers including tartrate-resistant acid phosphatase and RANK. OVx mice administered medicarpin (10.0 mg kg(-1) day(-1)) orally for 30 days had reduced formation of osteoclasts but increased formation of osteoprogenitor cells in BMCs compared with OVx + vehicle group. Medicarpin treatment to OVx mice maintained parameters of trabecular microarchitecure. Medicarpin exhibited no uterine estrogenicity. Our findings point towards direct and indirect inhibitory effects of medicarpin on osteoclastogenesis in vitro that contribute to its bone sparing effect in Ovx mice. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available